Biotechnology company Adicet Bio Inc (NASDAQ: ACET) announced on Monday that it has opened enrollment for a Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and ANCA-associated vasculitis (AAV).
The trial, which will assess safety and tolerability, has activated clinical sites for LN patients, with enrollment for SLE, SSc and AAV expected in Q4 2024.
ADI-001, an allogeneic gamma delta CAR T cell therapy targeting B-cells via an anti-CD20 CAR, recently received FDA Fast Track Designation for relapsed/refractory class III or IV LN.
The trial's secondary objectives will focus on cellular kinetics, pharmacodynamics and disease activity.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers